# First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers

> **NCT06625515** · PHASE1 · TERMINATED · sponsor: **Accent Therapeutics** · enrollment: 17 (actual)

## Conditions studied

- Advanced Solid Tumors
- Breast Cancer Recurrent
- Colorectal Cancer Metastatic
- Colon Cancer
- Rectal Adenocarcinoma
- Endometrial Cancer

## Interventions

- **DRUG:** ATX-559

## Key facts

- **NCT ID:** NCT06625515
- **Lead sponsor:** Accent Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2024-10-11
- **Primary completion:** 2026-01-09
- **Final completion:** 2026-01-09
- **Target enrollment:** 17 (ACTUAL)
- **Why stopped:** The study was terminated by sponsor based on the adverse event profile.
- **Last updated:** 2026-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06625515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06625515, "First-in-Human Study of ATX-559, an Oral Inhibitor of DHX9, in Patients With Advanced or Metastatic Solid Tumors, and Molecularly Defined Cancers". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT06625515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*